You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
雲南白藥(000538.SZ)去年投資錄鉅虧 證券投資明確逐漸減持並擇機退出
雲南白藥(000538.SZ)在深交所披露投資者調研會議記錄公告,稱2022年公司將投資股票和股票基金、股權基金的比例,從合計不得高於最近一個會計年度審計後淨資產的15%下調至8%。 公司表示,在證券投資領域,總體原則是逐步減倉,不再繼續增持。公司會在大家比較關心的二級市場證券投資上,明確的計劃就是逐漸減持,擇機地退出。 據財報的數據統計顯示,2021年雲南白藥投資中虧損最大的是小米集團(01810.HK),虧損14.04億元人民幣(下同),其次是恆瑞醫藥(600276.SH)和騰訊(00700.HK)(TCEHY.US)。公司已清倉騰訊、恆瑞醫藥、伊利集團(600887.SH)和中國生物製藥(01177.HK)。截至2021年末,雲南白藥證券、基金投資公允價值變動虧損19.29億元。(ta/s) ~
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account